Access and reimbursement pathways for digital health solutions and IVD devices

Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges

Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular attention is paid to software-based in vitro diagnostics (IVDs). With this point of view, a strong connection between DTx and IVDs is observed.

The recent paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” investigates the current regulatory scenarios and reimbursement approaches adopted for DTx and IVDs.

The initial assumption was that countries apply different regulations for the access to the market and adopt different reimbursement systems for both DTx and IVDs. The final aim was to provide a general comparative overview and identify those aspects that should be better addressed to support the adoption and commercialization of DTx and IVDs.

The paper “Access and reimbursement pathways for digital health solutions and in vitro diagnostic devices: Current scenario and challenges” is co-authored by Andrea Mantovani, Claudia Leopaldi, and Cassandra Maria Nighswander from Alira Health and Rossella Di Bidino, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Graduate School of Health Economics and Management (ALTEMS).

Related news

News September 8, 2023
Alira Health Partners With Col·legi de Metges de Barcelona
We are pleased to partner with Col·legi de Metges de Barcelona (CoMB), an institution that represents and serves the almost 39,000 physicians in Barcelona.
Market Access Spain Startups
Events August 10, 2023
12th EPP Life Sciences Pricing Forum
We are excited to speak at the 12th EPP Life Sciences Pricing Forum for pricing directors and executives in Life Sciences.
EU Market Access
Publications August 1, 2023
The EU Pharmaceutical Package: Impact on Orphan Medicinal Products
This article reviews the proposed changes in the EU Pharma Package for data protection related to orphan medicinal products (OMPs).
EU Pharma Regulatory
Events July 31, 2023
ESMO Congress
We are excited to join the ESMO Congress in Madrid. to disseminate the latest cutting-edge data for oncologists and other stakeholders.
Drug Development Market Access Oncology Spain
Publications July 25, 2023
Improving Access to Medicine: The Role of Pharma Companies in Emerging Markets
Our Market Access experts have identified risks and opportunities associated with improving access to medicines in emerging countries.
Market Access Pharma
Publications July 10, 2023
The EU Pharmaceutical Package: Regulatory Protection Changes
Our regulatory experts present a more detailed analysis of the proposed changes introduced to Regulatory Data Protection (RDP).
EU Pharma Regulatory
Blog June 30, 2023
Why You Need Market Access and How to Get Started
Start reading to learn about the importance of market access in pharma and MedTech and the key steps to get started.
Market Access MedTech Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.